Show simple item record

dc.contributor.authorMacLennan, Steven
dc.contributor.authorWilliamson, Paula R.
dc.contributor.authorBekema, Hendrika J
dc.contributor.authorCampbell, Marion
dc.contributor.authorRamsay, Craig
dc.contributor.authorN'Dow, James
dc.contributor.authorMacLennan, Sara
dc.contributor.authorVale, Luke
dc.contributor.authorLam, Thomas
dc.contributor.authorCOMPACTERS study group
dc.date.accessioned2018-05-03T23:01:26Z
dc.date.available2018-05-03T23:01:26Z
dc.date.issued2017-11
dc.identifier96485046
dc.identifier992a752f-d388-4b74-869c-018b8c788ac7
dc.identifier28346770
dc.identifier85018344505
dc.identifier.citationMacLennan , S , Williamson , P R , Bekema , H J , Campbell , M , Ramsay , C , N'Dow , J , MacLennan , S , Vale , L , Lam , T & COMPACTERS study group 2017 , ' A core outcome set for localised prostate cancer effectiveness trials ' , BJU International , vol. 120 , no. 5B , pp. E64-79 . https://doi.org/10.1111/bju.13854en
dc.identifier.issn1464-4096
dc.identifier.otherORCID: /0000-0002-2691-8421/work/61024728
dc.identifier.otherORCID: /0000-0003-1405-6964/work/61511044
dc.identifier.otherORCID: /0000-0003-4043-7349/work/128322849
dc.identifier.otherORCID: /0000-0001-5386-4097/work/128323508
dc.identifier.urihttp://hdl.handle.net/2164/10420
dc.descriptionAcknowledgements The authors wish to thank the following: Heather Bagley and Linda Pennet for their advice and assistance regarding patient and public involvement in research; Janice Forsyth and Sarah Murdoch for their assistance with logistics before and during the consensus meeting; Melanie Harper-Jones and Duncan Appelbe for their support in designing and managing the online Delphi survey and data; Vikki Entwistle for her advice during the protocol development stage; and Jane Blazeby and Liz Gargon for providing advice on Delphi survey and consensus meeting methods. Finally, we would like to thank all patients and HCPs who took part in the interview study and Delphi survey. Funded by Cancer Research Aberdeen and North East Scotland (CRANES) Sonacare Inc Sophiris Biocorp Inc Trod Medical Takeda pharmaceutical / Millenium Astellas Pierre Fabre Sanofi Pasteuren
dc.format.extent16
dc.format.extent91958
dc.language.isoeng
dc.relation.ispartofBJU Internationalen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectcore outcome seten
dc.subjectlocalised prostate canceren
dc.subjectclinical trialsen
dc.subjectconsensus processen
dc.subjectDelphi surveyen
dc.subjectconsensus group meetingen
dc.subjectR Medicineen
dc.subjectGeneral Medicineen
dc.subject.lccRen
dc.titleA core outcome set for localised prostate cancer effectiveness trialsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Academic Urology Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.CLSM College Officeen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.description.statusPeer revieweden
dc.identifier.doi10.1111/bju.13854
dc.date.embargoedUntil2018-05-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record